Stockreport

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Xilio Therapeutics, Inc.  (XLO) 
PDF Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma [Read more]